What Maypharm does

Maypharm is a Seoul, South Korea-based private company founded in 2009 that supplies Korean aesthetic devices, hyaluronic acid (HA) fillers, cosmetics, and botulinum toxin products for export to international markets. The firm operates in the medical aesthetics and beauty-products segment, with its value proposition centered on sourcing and distributing Korean-origin aesthetic products — a category that benefits from the international brand recognition of Korean beauty and aesthetics brands — to buyers in other geographies.

The company's product portfolio spans four adjacent categories: capital equipment (aesthetic devices), injectables (HA fillers and botulinum toxin), and topical/skincare (cosmetics). This breadth indicates a multi-line export business rather than a single-product specialist. The firm has 11-50 employees per available firmographic data, consistent with a small-to-mid-sized export/distribution operation. However, the input data contains no information on specific product names, SKUs, technical specifications, manufacturing vs. sourcing model (OEM/ODM vs. proprietary), pricing, distribution channels, or named customers, so the underlying business mechanics cannot be verified beyond the descriptive level.

The business model appears to be product distribution and export, with revenue generated through the sale of Korean-made aesthetic products to international buyers (likely distributors, clinics, medspas, or wholesalers, though this is not confirmed in the input). No revenue figures, pricing structures, contract terms, or capital raise history are available. The company's website (maypharm.net) is currently unreachable (403 Forbidden), which is a relevant operational diligence finding. The investment-relevant unknowns include: (1) whether Maypharm is a brand-owner/manufacturer or a trading/distribution entity, (2) the geographic mix of its export markets and regulatory approval footprint, (3) customer concentration and channel structure, and (4) the actual revenue scale and growth trajectory of the business.

Name

Maypharm

Legal name

Maypharm

Website

https://maypharm.net

Company type

Private

Founded year

2009

Headcount range

11–50 employees

Short description

Maypharm is a Seoul, South Korea-based private company founded in 2009 that exports Korean aesthetic devices, hyaluronic acid fillers, cosmetics, and botulinum toxin products to international markets. It operates with 11-50 employees in the medical aesthetics distribution segment.

Ownership category

akta.pro rank

Product category

Medical Aesthetics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Soap and Cleaning Compound Manufacturing (32561), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI), Hand & Body Care (Lotions, Creams, Body Oils) (CRADANAC)

Keywords

• Aesthetic medical devices
• HA dermal fillers
• Botulinum toxin products
• Medical aesthetics export
• Cosmetic product distribution

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales

Core offering

Maypharm provides Korean-made aesthetic devices, hyaluronic acid (HA) dermal fillers, cosmetics, and botulinum toxin products for global export. The company supplies these medical aesthetic and cosmetic product categories to overseas buyers from its base in Seoul, South Korea.

Differentiator

Problem solved

Functional benefit

Products and services

• Korean aesthetic devices Medical aesthetic devices manufactured or sourced in Korea and exported by Maypharm for use by medical aesthetic clinics and practitioners internationally.
• HA (hyaluronic acid) dermal fillers Hyaluronic acid-based injectable dermal fillers supplied by Maypharm for medical aesthetic and dermatology use, exported to international buyers.
• Cosmetics Cosmetic products manufactured or sourced in Korea and exported by Maypharm for distribution to international beauty and aesthetic buyers.
• Botulinum toxin products Botulinum toxin preparations supplied by Maypharm for medical aesthetic and clinical use, exported to international buyers.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights3 records

Broad incumbents

• Galderma: Global dermatology and aesthetics leader with a broad portfolio of HA fillers and skincare products. Comparable as a large incumbent competing for the same clinic and distributor customers Maypharm serves, though with proprietary R&D and global manufacturing.
• AbbVie (Allergan Aesthetics): Owner of Botox and the Juvederm filler franchise, the dominant global player in aesthetic injectables. Comparable as the benchmark incumbent whose regulatory and commercial actions shape the export market Maypharm operates in.
• LG Chem: Korean chemical/pharma conglomerate with a growing aesthetics business (e.g., Yvoire HA fillers). Comparable as a large Korean incumbent operating in both pharmaceutical manufacturing and aesthetic exports.
• Ipsen: Global pharmaceutical company with a leading aesthetic toxin franchise (Dysport/Azzalure). Comparable as a large incumbent whose toxin products directly compete with the Korean botulinum toxin category Maypharm distributes.

Direct peers

• Medytox: Korean biopharma specializing in botulinum toxin and filler products for global markets. Comparable as a Seoul-headquartered Korean aesthetics company exporting injectables internationally.
• Daewoong Pharmaceutical: Korean pharmaceutical company producing Nabota botulinum toxin and exporting aesthetics products globally. Comparable as a Korean-origin manufacturer/exporter of aesthetic injectables.
• Hugel: Korean manufacturer of botulinum toxin (Botulax) and HA fillers with significant international export operations. Directly comparable to Maypharm as a Seoul-based Korean aesthetics exporter serving global markets.
• Classys: Korean manufacturer of aesthetic devices (e.g., Ultraformer HIFU) exporting worldwide. Comparable as a Seoul-based Korean aesthetics-device exporter with a similar global distribution profile to Maypharm's device line.

Emerging players

• Sinclair Pharma: Aesthetics-focused company with a portfolio of HA fillers and bio-stimulators distributed internationally. Comparable as a mid-sized aesthetics exporter competing in the same clinic channels Maypharm targets.

Regional players

• Bloomage Biotech: Chinese-origin hyaluronic acid giant expanding into aesthetics and skincare. Comparable as a major HA-ingredient and finished-product player competing for the same global aesthetics customers, primarily from an Asia-Pacific base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/Maypharmkorea
• LinkedInlinkedin.com/company/maypharm

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maypharm